Press release Communiqué de presse

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter

Press release Communiqué de presse


June 19, 2006 19 June, 2006

Dr. David White to Become Principal Researcher and Chair of Scientific Advisory Board


Kelowna, B.C. -- Pheromone Sciences Corp. ("Pheromone") is pleased to announce that Dr. David White of the University of Western Ontario has agreed to become the principal researcher for the Company's diabetes research project and has accepted an appointment as Chair of the Company's Scientific Advisory board ("SAB"). Pheromone recently completed a $3.2 million private placement to fund this project, and it will be the Company's primary research focus.

As SAB Chair, Dr. White's first responsibility is to recruit members to the SAB who have significant standing in the community of diabetic and xenotransplantation researchers. "The scientists on the SAB shortlist are some of the finest minds in the field and they have an intricate understanding of the science of this project, " states Dr. White. "I believe their contributions will be invaluable in ensuring the best design and execution of this diabetes product development project"." The SAB will provide oversight of the Company's research efforts and provide scientific input and interpretation of the project's methodology, progression and results.

About Dr. White

Dr White graduated from the Universities of Surrey and Cambridge and in 1975 was awarded a PhD in Immunology from Cambridge. He was Board Certified in Pathology in 1984 (MRCPath) and elected as a fellow of the college in 1995 (FRCPath). Dr White holds appointments on the Editorial Board of several major international transplantation journals, has served as a member of government advisory committees, and has been awarded a number of academic prizes for his work. He has published over 300 scientific papers on subjects related to transplant immunology.

Dr. White first became interested in transplantation while undertaking research at the Department of Surgery at Cambridge University in the 1970s. In conjunction with Professor Sir Roy Calne, he undertook much of the original experimental and clinical work that led to the development of the immunosuppressive drug Cyclosporin A. The drug became pivotal in preventing organ rejection following transplantation and has allowed new transplantation procedures to be developed.

His research into the immunological process underlying rejection of organ transplants led him to investigate how the immune system could be modified to enable successful transplantation of non-human organs - potentially solving the 'organ donor crisis'. These studies led Dr White in 1992 to create the world's first genetically engineered pigs

whose organs and tissues were modified for transplantation into humans. In 1984 he and transplant surgeon John Wallwork founded Imutran Limited, which became a wholly owned subsidiary of Novartis Pharma AG in 1996., and Dr White was appointed to the Novartis Global Research Management Board. In 2000 Dr White was appointed the Novartis/Stiller Professor of Xenotransplantation at the University of Western Ontario.

About the Research Project

Pheromone's research project is intended to lead to an USFDA licensed procedure for treating diabetes by transplanting into humans a device containing pig islet and Sertoli cells. The islet cells produce insulin almost identical to that found in humans, and the Sertoli cells naturally protect the islet cells from attack by the body's immune system. The research is based on several proof of concept experiments completed by Dr. White and others.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing medical technologies.

ON BEHALF OF THE BOARD "Dev Randhawa" Dev Randhawa, President

For further information contact:

Mr. Phil Morehouse Pheromone Sciences Corp. TEL: (250) 868-8177 FAX: (250) 868-8493

Mr. Justin Leushner Sertonex Inc. TEL: (519) 639-7867 FAX: (519) 858-5142